Benjamin Walbaum, Medical Oncologist at Pontifical Catholic University of Chile, shared a post on LinkedIn:
“My Weekly Take, Breast Cancer (Feb 9–16).
Precision Treatment With Artificial Intelligence-Assisted Subtyping Enhances Therapeutic Efficacy in HR+/HER2- Breast Cancer: The LINUX Trial.
Cancer Cell
- AI-driven molecular subtyping improves treatment allocation and enhances therapeutic efficacy in HR+/HER2− disease.
Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer.
Clinical Cancer Research
- Early CNS screening may improve outcomes in HER2+ metastatic disease and deserves prospective validation.
Validation of the HER2DX Genomic Test in First-Line Advanced HER2-Positive Breast Cancer
npj Breast Cancer.
- HER2DX refines prognostication beyond clinical factors in first-line metastatic HER2+ disease.
Circulating Tumor DNA in Neoadjuvant Endocrine Therapy for Early Breast Cancer.
ESMO Open
- ctDNA dynamics may guide adaptive endocrine strategies in early HR+ breast cancer.
Inadequate Ovarian Function Suppression in Premenopausal Early Breast Cancer.
ESMO Open
- Suboptimal ovarian suppression remains common and may compromise adjuvant endocrine efficacy.
Extracellular Matrix Mediates Circulating Tumor Cell Clustering in TNBC Metastasis.
Nature Communications
- ECM-driven CTC clustering is a key biological driver of TNBC metastasis and a potential therapeutic target.
Association Between Alcohol Consumption and Breast Cancer Incidence and Prognosis.
The Breast
- Alcohol increases breast cancer incidence in a dose-dependent manner but does not worsen breast cancer–specific survival.
Prognostic Significance of Isolated Tumor Cells in Nodal Evaluation.
JCO Precision Oncology
- Isolated tumor cells carry independent prognostic significance and may impact adjuvant decision-making.
Full newsletter attached. Happy to discuss how these data may influence clinical practice.”
Other articles about Breast Cancer on OncoDaily.